X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

To Reach Emission Goals, Seven Pharma CEOs Band Together

Content Team by Content Team
14th November 2022
in Clinical Trials, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Seven CEOs of pharmaceutical companies, including GSK, AstraZeneca, Merck, Roche, Novo Nordisk, Samsung Biologics, and Sanofi, have launched a collaborative effort to meet short-term emission reduction goals and hasten the implementation of net zero health systems.

The Sustainable Markets Initiative (SMI) Health Systems Task Force, a public-private collaboration established at COP26, is bringing together the global health industry for the first time to cut greenhouse emissions.

To help with achieving emission targets, common standards

The Task Force will set uniform criteria to encourage providers to take action throughout the supply chain in order to reduce emissions throughout supply chains as well as clinical trials.

The Task Force’s member companies will use digital health solutions in the following ways:

  • By 2023, they will have developed and committed to a uniform methodology for measuring emissions from Phase II and III clinical trials. Companies plan to start disclosing emissions for these tests in 2025.
  • By no later than 2030, align new studies with businesses’ decarbonization plans and set emission goals for clinical trials.
  • Make vendors for clinical trials and clinical research organisations swear to track and cut back on emissions. The groups will have a structure via digital tools to keep track of everything.
  • Make sure that an assessment of how digital technologies can reduce emissions appears in more than 90% of trials that begin in 2025.

The Task Force and the Alliance for Transformative Action on Climate and Health shall collaborate. Over 60 nations dedicated to climate security and low-carbon health systems will receive recommendations from the cooperation at the ministerial level.

Leaders from the World Health Organization (WHO), UNICEF, academic institutions, and non-governmental organisations are also members of the SMI Health Systems Task Force.

According to the Director-General of the WHO, Dr. Tedros Adhanom Ghebreyesus, failing to maintain the 1.5°C goal will have lasting repercussions on world health. The promises made show how effective public-private partnerships can be in bringing about positive, long-lasting change.

In whitepapers titled The Digital Solution for Sustainability in Clinical Research and Decarbonising Healthcare Supply Chains, the Task Force offers suggestions and doable steps.

Previous Post

Sustainable Pharmaceutical Packaging: Removing Barriers

Next Post

GHIT Fund Invests ¥790M In Ignored Tropical Disease Products

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Allergan Expands PLEDGE Clinical Research

GHIT Fund Invests ¥790M In Ignored Tropical Disease Products

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In